Table of contents
In this issue
p599 | doi:10.1038/nrd1171
Editorial: With a little help from your friends...
p601 | doi:10.1038/nrd1172
Research Highlights
Rational drug design: We're prodrug!
p603 | doi:10.1038/nrd1161
Neurodegenerative diseases: As one door closes, another opens
p604 | doi:10.1038/nrd1162
Virtual screening: Artificial intelligence
p604 | doi:10.1038/nrd1168
Antifungals: Doing the two step
p605 | doi:10.1038/nrd1167
High-throughput screening: Combine and conquer
p606 | doi:10.1038/nrd1165
Diabetes: Connectin' through adiponectin
p606 | doi:10.1038/nrd1166
Lead discovery: Guided by nature
p607 | doi:10.1038/nrd1163
In brief
Inflammatory Disease | AntiCancer Drugs | Cardiovascular Disease | Anti-Allergic Drugs
p607 | doi:10.1038/nrd1170
Neurodegenerative diseases: Spot the difference
p608 | doi:10.1038/nrd1164
News and Analysis
Patent watch
Please show your working | Battle of the generics
p608 | doi:10.1038/nrd1169
From the analyst's couch
Oncology's trials
p609 | doi:10.1038/nrd1158
Fresh from the Pipeline
Bortezomib
p611 | doi:10.1038/nrd1159
Reviews
Pharmacophylogenomics: genes, evolution and drug targets
David B. Searls
p613 | doi:10.1038/nrd1152
Toxicity of antiretroviral therapy and implications for drug development
Andrew Carr
p624 | doi:10.1038/nrd1151
Therapeutic approaches to innate immunity: severe sepsis and septic shock
Elias Lolis & Richard Bucala
p635 | doi:10.1038/nrd1153
Mild cognitive impairment clinical trials
Ronald C. Petersen
p646 | doi:10.1038/nrd1155
Article series: A guide to drug discovery
A guide to drug discovery: Logistics of process R&D: transforming laboratory methods to manufacturing scale
Hans-Jürgen Federsel
p654 | doi:10.1038/nrd1154
Perspectives
Opinion
Drug research: myths, hype and reality
Hugo Kubinyi
p665 | doi:10.1038/nrd1156
Opinion
Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism
Jeremy K. Nicholson & Ian D. Wilson
p668 | doi:10.1038/nrd1157
Top of page
